Peter Paschka
About
Peter Paschka is a scholar working on Hematology, Molecular Biology and Genetics.
According to data from OpenAlex, Peter Paschka has authored 93 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Hematology, 42 papers in Molecular Biology and 38 papers in Genetics. Recurrent topics in Peter Paschka's work include Acute Myeloid Leukemia Research (58 papers), Chronic Myeloid Leukemia Treatments (33 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (21 papers). Peter Paschka is often cited by papers focused on Acute Myeloid Leukemia Research (58 papers), Chronic Myeloid Leukemia Treatments (33 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (21 papers). Peter Paschka collaborates with scholars based in Germany, United States and Italy. Peter Paschka's co-authors include Guido Marcucci, Clara D. Bloomfield, Krzysztof Mrózek, Susan P. Whitman, Richard A. Larson, Konstanze Döhner, Jonathan E. Kolitz, Andrew J. Carroll, Hartmut Döhner and Lars Bullinger and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and Nature Genetics.
In The Last Decade
Peter Paschka
91 papers receiving 6.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Peter Paschka Germany | 36 | 4.6k | 3.3k | 2.0k | 1.4k | 932 | 93 | 6.3k | ||
| Krzysztof Mrózek United States | 53 | 7.7k 1.7× | 5.0k 1.5× | 2.4k 1.2× | 2.0k 1.4× | 2.7k 2.9× | 174 | 10.2k | ||
| Alexander Kohlmann Germany | 44 | 3.6k 0.8× | 3.8k 1.1× | 1.8k 0.9× | 1.4k 1.0× | 993 1.1× | 181 | 7.5k | ||
| Claudia Haferlach Germany | 53 | 6.9k 1.5× | 3.5k 1.1× | 4.3k 2.2× | 1.3k 0.9× | 1.6k 1.7× | 449 | 9.7k | ||
| George S. Vassiliou United Kingdom | 36 | 4.2k 0.9× | 5.1k 1.5× | 4.4k 2.3× | 1.1k 0.8× | 260 0.3× | 108 | 8.4k | ||
| Taghi Manshouri United States | 43 | 3.1k 0.7× | 3.0k 0.9× | 3.2k 1.6× | 486 0.3× | 306 0.3× | 143 | 6.2k | ||
| Claudia Schoch Germany | 56 | 8.9k 1.9× | 5.1k 1.5× | 3.4k 1.7× | 871 0.6× | 2.9k 3.1× | 194 | 11.4k | ||
| Christopher A. Eide United States | 28 | 2.3k 0.5× | 1.6k 0.5× | 1.6k 0.8× | 322 0.2× | 293 0.3× | 97 | 3.9k | ||
| Claudia D. Baldus Germany | 36 | 3.2k 0.7× | 2.3k 0.7× | 1.0k 0.5× | 879 0.6× | 1.3k 1.4× | 124 | 4.6k | ||
| T J Ley United States | 13 | 3.2k 0.7× | 3.3k 1.0× | 923 0.5× | 1.1k 0.8× | 397 0.4× | 13 | 4.9k | ||
| Brigitte Mohr Germany | 30 | 3.5k 0.8× | 1.3k 0.4× | 1.3k 0.6× | 389 0.3× | 933 1.0× | 79 | 4.2k |
Countries citing papers authored by Peter Paschka
Since
Specialization
Citations
This map shows the geographic impact of Peter Paschka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Paschka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Paschka more than expected).
Fields of papers citing papers by Peter Paschka
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Peter Paschka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Paschka. The network helps show where Peter Paschka may publish in the future.
Co-authorship network of co-authors of Peter Paschka
This figure shows the co-authorship network connecting the top 25 collaborators of Peter Paschka. A scholar is included among the top collaborators of Peter Paschka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Paschka. Peter Paschka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bergner, Raoul, et al.. (2022). Single Center Experience Using Monoclonal COVID-19 Antibodies in the Management of Immunocompromised Patients with COVID-19. Microorganisms. 10(12). 2490–2490.
2.
Krzykalla, Julia, Silke Kapp‐Schwoerer, Verena I. Gaidzik, et al.. (2021). Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with <i>nucleophosmin1</i>-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. Haematologica. 106(11). 2986–2989.
3.
Loges, Sonja, Michael Heuser, Carlos E. Vigil, et al.. (2018). Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS. Blood. 132(Supplement 1). 2672–2672.
4.
Gerstung, Moritz, Elli Papaemmanuil, Sancha Martin, et al.. (2017). Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nature Genetics. 49(3). 332–340.
5.
Döhner, Konstanze, Peter Paschka, & Hartmut Döhner. (2015). Akute myeloische Leukämie. Der Internist. 56(4). 354–363.
6.
Paschka, Peter, Richard F. Schlenk, Hartmut Döhner, et al.. (2011). Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups. Leukemia. 25(11). 1728–1738.
7.
Paschka, Peter, Richard F. Schlenk, Verena I. Gaidzik, et al.. (2010). IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication. Journal of Clinical Oncology. 28(22). 3636–3643.
8.
Becker, Heiko, Guido Marcucci, Kati Maharry, et al.. (2009). Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology. 28(4). 596–604.
9.
Marcucci, Guido, Kati Maharry, Michael D. Radmacher, et al.. (2008). Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology. 26(31). 5078–5087.
10.
Paschka, Peter. (2008). Core Binding Factor Acute Myeloid Leukemia. Seminars in Oncology. 35(4). 410–417.
11.
Marcucci, Guido, Michael D. Radmacher, Kati Maharry, et al.. (2008). MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia. New England Journal of Medicine. 358(18). 1919–1928.
12.
Mrózek, Krzysztof, Guido Marcucci, Peter Paschka, & Clara D. Bloomfield. (2008). Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Current Opinion in Oncology. 20(6). 711–718.
13.
Ernst, Thomas, Philipp Erben, Martin Müller, et al.. (2008). Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica. 93(2). 186–192.
14.
Müller, Martin, Giuseppe Saglio, Feng Lin, et al.. (2007). An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica. 92(7). 970–973.
15.
Liu, Shujun, Rebecca B. Klisovic, Tamara Vukosavljevic, et al.. (2007). Targeting AML1/ETO-Histone Deacetylase Repressor Complex: A Novel Mechanism for Valproic Acid-Mediated Gene Expression and Cellular Differentiation in AML1/ETO-Positive Acute Myeloid Leukemia Cells. Journal of Pharmacology and Experimental Therapeutics. 321(3). 953–960.
16.
Liu, Zhengyu, Shuang Liu, Zhiliang Xie, et al.. (2007). Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. Nucleic Acids Research. 35(5). e31–e31.
17.
Ugurel, Selma, Ralf Hildenbrand, Paul La Rosée, et al.. (2005). Lack of clinical efficacy of imatinib in metastatic melanoma. British Journal of Cancer. 92(8). 1398–1405.
18.
Burchert, Andreas, Ying Wang, Dawei Cai, et al.. (2005). Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia. 19(10). 1774–1782.
19.
Paschka, Peter, Kirsten Merx, & Andreas Hochhaus. (2004). Molecular Surveillance of Chronic Myeloid Leukemia Patients in the Imatinib Era – Evaluation of Response and Resistance. Acta Haematologica. 112(1-2). 85–92.
20.
Müller, Martin C., Peter Paschka, Kirsten Merx, et al.. (2004). Standardization of Preanalytical Factors for Minimal Residual Disease Analysis in Chronic Myelogenous Leukemia. Acta Haematologica. 112(1-2). 30–33.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Krzysztof Mrózek Breakdown of academic impact, for papers by Alexander Kohlmann Breakdown of academic impact, for papers by Claudia Haferlach Breakdown of academic impact, for papers by George S. Vassiliou Breakdown of academic impact, for papers by Taghi Manshouri Breakdown of academic impact, for papers by Claudia Schoch Breakdown of academic impact, for papers by Christopher A. Eide Breakdown of academic impact, for papers by Claudia D. Baldus Breakdown of academic impact, for papers by T J Ley Breakdown of academic impact, for papers by Brigitte Mohr